Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hg Capital Trust Plc LSE:HGT London Ordinary Share GB00BJ0LT190 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 0.49% 305.00 304.00 305.50 306.00 301.50 305.00 694,729 16:26:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 15.5 11.5 2.9 103.7 1,253

Hg Capital Share Discussion Threads

Showing 76 to 100 of 200 messages
Chat Pages: 8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
28/2/2013
09:18
HGT assets are mainly denominated in euros, and since gbp has fallen about 7% vs Euro since the start of the year, this recent jump since January is primarily just a refection of that currency move I suspect.
woracle
28/2/2013
09:07
Yes what a great run.....am out now, and hoping for a decent rise in PLIS which is well overdue!
jaf111
28/2/2013
09:02
Wow, and I nearly sold my HGTS last Monday as I was on the verge of giving up hope before the end of May !
morgs
27/2/2013
16:30
Yes very nice rise.....glad i spotted this one!!!!
jaf111
27/2/2013
16:29
Strong recovery with recent euro strength vs gbp... maybe a hint of a disposal even.
woracle
19/2/2013
08:33
well warrant on move today
jaws6
14/9/2012
08:10
Subs looking ridiculously cheap (53 - 57p) with shares on 1,015 - 1,020p = intrinsic value of 65 - 70p......
jaf111
07/9/2012
06:30
RNS out on HGt
jaws6
06/9/2012
20:50
Now the 'city suits' are back from Tuscany, we may well see that discount to NAV narrowed and perhaps even see the mkt. share price trade ahead of NAV again. The boss retires soon. He was polite enough to wait till the H1 results had printed before committing another £700k of HGT to his pension fund. At this level, with the 950 Oct. 2012 exercise hurdle crossed, the subs. should move penny for penny with the offer price of HGT. I'll 2nd. your motion 'fingers crossed'! By the way, i) IG have a mkt. on HGTS. Guaranteed stops, too! ii) There is a 'ghost-town' HGTS advfn thread.
2baffled
06/9/2012
20:18
Subs failed to get to 60p tody.....BUT still a decent rise of 33% to 53p mid! Should see 60p minimum tomorrow just to clear the discount, and could / should go higher still if the shares continue their rally. Fingers crossed!!!!!!!
jaf111
06/9/2012
11:51
Tks for good link
jaws6
06/9/2012
11:46
Seen this? CEO speaks ........... 10 min vid. Auto-starts on opening. http://mediazone.brighttalk.com/comm/h2glenfern/c45e746d72-32351-4351-36401
2baffled
06/9/2012
11:18
Indeed 2baffled....and based on their track record that NAV is ultra conservative...their last sale increased NAV per share by 50p i think
jaf111
06/9/2012
11:09
HGT; diluted NAV = 1166.9.
2baffled
06/9/2012
11:02
Well the 50p target was reached before lunch....but with shares up to 1,012p the subs remain on a discount so really 60p should be on the cards by COB today!!!
jaf111
06/9/2012
07:40
2baffled Tks,did not know or would have bought there but got HGT, thanks to Marben for this.
jaws6
06/9/2012
07:19
Subs going well this morning - but still in a discount!!!! Should get to 50p today.......
jaf111
05/9/2012
20:54
jaws, Have you considered the sub. share [HGTS, ISA-able]? (HG Capital Subscription shares give the holder the right to buy one HG Capital share at 950p on 31 May or 31 October in 2011 and 2012, or at 1,025p if exercised on 31 May 2013). Compare [ADVFN Charts];- HGT; http://uk.advfn.com/cmn/chrt/chrt_wrap.php?epic=hgts&name=&type=1&sprd=0&size=2&period=7&freq=1&date1_day=27&date1_month=10&date1_year=1986&date2_day=05&date2_month=09&date2_year=2012&ind_type1=0&ind1_1=&ind2_1=&ind_type2=0&ind1_2=&ind2_2=&ind_type3=0&ind1_3=&ind2_3= Against;- HGTS; http://uk.advfn.com/cmn/chrt/chrt_wrap.php?epic=HGT&name=&type=1&sprd=0&size=2&period=7&freq=1&date1_day=27&date1_month=10&date1_year=1986&date2_day=05&date2_month=09&date2_year=2012&ind_type1=0&ind1_1=&ind2_1=&ind_type2=0&ind1_2=&ind2_2=&ind_type3=0&ind1_3=&ind2_3=
2baffled
05/9/2012
11:45
at last seen 990 again
jaws6
17/8/2012
07:37
HgCapital announces the sale of Mercury Pharma London, 17 August 2012: HgCapital has today announced the sale, for £465 million, of Mercury Pharma, the UK-based speciality pharmaceutical company, to Cinven, the European private equity firm. Following the sale of Mercury Pharma, 20% of invested capital will have been realised by the HgCapital 2009 vintage fund, HgCapital 6. Since the start of the global economic downturn in Q3 2008, HgCapital has realised a total of 15 investments, returning approximately £1.6 billion in proceeds to clients at a time of economic uncertainty. HgCapital's 2006 vintage fund, HgCapital 5 has already returned more than 120% of invested capital to date, from only five full and one partial exit including SLV (4.0x original cost, 45% IRR), Visma (4.1x original cost, 34% IRR) and SHL (3.1x original cost, 25% IRR). Mercury Pharma is a speciality pharmaceutical company focused on the sale of niche prescription off-patent products. Mercury Pharma's portfolio is underpinned by strong intellectual property rights with 91% of revenue from owned-IP products. Based in the UK, the company was founded in 1989 and was listed on the London Stock Exchange from 1998-2009. It has 187 employees worldwide, including an operations centre in India and a direct sales presence in the UK, Ireland and the Netherlands. Mercury Pharma was acquired by funds managed by HgCapital in December 2009 in a complex public to private transaction. The HgCapital Healthcare Team was attracted by the highly flexible, asset-light business model, focused on selling a diverse portfolio of well positioned products. Since taking Mercury Pharma private, HgCapital has taken an active approach towards building value in the business. Mercury, under a new management team, quickly refocused on its niche pharmaceutical business, disposing of all the non-core consumer related businesses. Significant investment in the pharmaceutical business has been focussed on building a best in class business development team to drive long term sales growth. Further investment in improving quality and supply chain effectiveness has helped to drive significant improvements in profit. As a result of these changes Mercury Pharma has nearly doubled EBITDA under HgCapital's ownership. Philipp Schwalber, Head of HgCapital's Healthcare team, said: "Mercury Pharma is the first exit for HgCapital 6, the second realisation by HgCapital's Healthcare Team in the last two years, and the most recent in a long line of public-to-private success stories for HgCapital. We initially identified the speciality pharmaceutical niche in 2007 and tracked Mercury Pharma for a number of years before launching our public-to-private offer in 2009. The realisation of Mercury Pharma marks the continued development of HgCapital's investment focus in the healthcare sector, as we continue to seek out businesses that enjoy niches of secular growth despite the challenges facing much of the healthcare space." Commenting on the realisation, Lisa Stone, a Partner in HgCapital's Portfolio Management team, said: "The success of Mercury Pharma is a terrific example of HgCapital's commitment to building robust, healthy and growing businesses. All the hard work from Philipp and the management team, in refocusing the business and investing in growth, has paid off, enabling us to deliver a great result for clients in a challenging market."
damanko
03/7/2012
18:11
Good RNS ,hold some of this .Will add if drop below 900
jaws6
03/7/2012
08:10
HgCapital Trust's NAV rises on realisation of SHL HgCapital has agreed to sell its investment in SHL. Upon completion of the transaction which is expected to happen early in August 2012, HgCapital Trust plc, the listed investment trust which invests in all HgCapital's deals alongside its institutional clients, will realise estimated cash proceeds of approximately £27.1 million. This represents an uplift of £5.4 million over the carrying value of £21.7 million in the Net Asset Value (NAV) of the Trust at 31 May 2012 which was based on the Directors' most recent valuation. On completion, the transaction will increase NAV per share by approximately 17.2 pence (basic) and 14.7 pence (fully diluted*). Based on the 31 May 2012 NAV and the impact of this transaction, the NAV of HgCapital Trust plc is estimated to be £349.1 million (1,096.9 pence per share basic; 1,075.3 pence per share fully diluted*). The sale proceeds represent a multiple of more than three times the original cost of £9.0 million. Based on the 31 May 2012 NAV and the effect of this transaction, liquid resources (including a £40 million undrawn bank facility) are estimated to increase to £100.5 million (29.2% of the estimated NAV). *The calculation of fully diluted earnings per share assumes that all subscription shares in issue are exercised at their minimum price of 950 pence. Set out below is the text of a press release issued today by HgCapital announcing the transaction. HgCapital announces the sale of SHL London, 3 July 2012: HgCapital has today announced the sale of SHL, the global leader in talent measurement, to The Corporate Executive Board Company ("CEB") (NYSE: EXBD) for $660 million. SHL was acquired by funds managed by HgCapital in October 2006 as a public to private transaction and subsequently merged with Previsor, a US based competitor, in January 2011. The sale to CEB represents an investment multiple in excess of 3.1x original cost and a gross IRR of 26% over the investment period for HgCapital's investors. The sale of SHL represents HgCapital's sixth realisation from its HgCapital 5 Fund, which now has delivered a realised investment multiple and IRR of 2.7x and 30% respectively. It will have returned over 120% of invested capital back to investors since HgCapital 5 was raised in 2006, with seven active investments still remaining in the portfolio. Since the start of the global economic downturn in the autumn of 2008, HgCapital has been an active seller realising a total of twelve investments over this period (versus an active unrealised portfolio of 24 investments) and returning approximately £1.1 billion in proceeds to clients at a time of economic uncertainty
damanko
18/5/2012
16:49
Further to my report on the Hg Capital Investment trust (http://sharesoc.ning.com/xn/detail/6389471:Comment:17108 ), I can report that Hg Capital's portfolio manager for their care home businesses (including Voyage) has called me to explain their quality procedures, as promised. Firstly, he pointed out that their homes specialised in high-acuity care, rather than elderly care. Fortunately, this care sub-sector is falling under less financial pressure than the much bigger elderly care sector. Secondly, he was able to report that a) comprehensive quality reports relating to their businesses were reviewed at each monthly Board meeting; b) quality audits, including unannounced inspections, were conducted by their own audit team; c) a confidential whistleblower line was publicised in each of their homes. He also described further measures they were taking to ensure that the highest ethical standards were maintained. Of course, this is in additon to the CQC inspections in the UK. I feel pretty confident that the company is doing as much as it reasonably can to ensure that residents are treated with dignity and that their needs are met. Regards, Mark
marben100
17/5/2012
00:54
Hi Kimboy2, No specifics on sales, but there was an indication that the company had considerable interest in some of its assets and might make realisations within the next 6 months. Given current market turmoil, personally I'm not counting on anything short term - so if they do make any decent realisations, that'll be a bonus. In the meantime, just happy to sit and wait - and add to my already proportionately large holding if the share price falls much further! Cheers, Mark
marben100
15/5/2012
14:50
Earlier this month is was reported that they'd put Mercury Pharma (Goldshield) up for sale. http://www.altassets.net/private-equity-news/by-news-type/deal-news/hgcapital-puts-mercury-pharma-on-the-block.html
rambutan2
Chat Pages: 8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
HGT
Hg Capital
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201123 16:41:30